Biomedicare India Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 31-07-2024
- Paid Up Capital ₹ 0.40 M
as on 31-07-2024
- Company Age 30 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 M
as on 31-07-2024
- Revenue 28.52%
(FY 2023)
- Profit 61.15%
(FY 2023)
- Ebitda 77.48%
(FY 2023)
- Net Worth 28.39%
(FY 2023)
- Total Assets 0.13%
(FY 2023)
About Biomedicare India
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.40 M.
The company currently has active open charges totaling ₹1.00 M.
Virender Kumar and Shrey Kamboj serve as directors at the Company.
- CIN/LLPIN
U74899DL1994PTC058066
- Company No.
058066
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Mar 1994
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Biomedicare India Private Limited offer?
Biomedicare India Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement, Common Disease Medicines, Eye Drops, Anti Infective Drugs & Medicines, Antiviral Drugs.
Who are the key members and board of directors at Biomedicare India?
Board Members(2)
Financial Performance and Corporate Structure Insights of Biomedicare India.
Biomedicare India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 28.52% increase. The company also saw a substantial improvement in profitability, with a 61.15% increase in profit. The company's net worth Soared by an impressive increase of 28.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biomedicare India?
In 2023, Biomedicare India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shrey Nutraceuticals And Herbals Private Limited
Active
22 years 5 months Virender Kumar and Shrey Kamboj are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 03 Dec 2022 | ₹1.00 M | Open |
How Many Employees Work at Biomedicare India?
Biomedicare India has a workforce of 6 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biomedicare India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biomedicare India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
